Clinical Trial

Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial

Study acronym: BeeVenom-CKD
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 28, 2025 (before its estimated October 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effectiveness of bee venom injections as a treatment for chronic kidney disease (CKD)-mineral bone disorder (MBD) in patients undergoing hemodialysis. MBD is a common complication in CKD patients, leading to abnormal mineral metabolism, bone disease, and increased cardiovascular risks. Current treatments are often inadequate and can have significant side effects. In this study, we will compare the effects of bee venom injections with standard care treatments in hemodialysis patients. Bee venom is known for its potential anti-inflammatory and immunomodulatory properties, which may help improve mineral metabolism and bone health regulation in these patients. By stimulating regulatory T cells (Tregs) through bee venom, we aim to reduce inflammation and restore bone health. We hope to answer whether bee venom can effectively reduce mineral bone disorder markers (such as calcium, phosphorus, and parathyroid hormone levels) and improve bone density in hemodialysis patients. The results could lead to a new treatment option for CKD-MBD, improving patient outcomes and quality of life.
Trial Details
NCT Number NCT06901102
Lead Sponsor Mansoura University
Conditions Chronic Kidney Disease, Bee Venom, Hemodialysis
Enrollment 60 participants
Start Date 2025-04-10
Primary Completion 2025-10-10 (estimated)
Study Completion 2025-10-20 (estimated)
Updated on ClinicalTrials.gov 2025-03-28